- World rank, all time
- #28,940 of 42,892
- Rank in United States
- #6,194 of 8,685
- Research works
- 185 ▲ 49% vs 2013–17
- Citations
- 3.7k 20.2 per fractional work
- Top-10% rate
- 17.0% record average 16.5%
- Open access
- 45% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Nursing, 5.2×. Every wedge is a field page.
- Nursing 5.2×
- Immunology and Microbiology 4.6×
- Pharmacology, Toxicology and Pharmaceutics 3.9×
- Biochemistry, Genetics and Molecular Biology 2.9×
- Chemistry 2.8×
- Economics, Econometrics and Finance 2.7×
- Medicine 2.5×
- Business, Management and Accounting 1.1×
- Veterinary 0.8×
- Materials Science 0.5×
- Agricultural and Biological Sciences 0.4×
- Computer Science 0.3×
- Neuroscience 0.3×
- Engineering 0.2×
- Psychology 0.2×
- Health Professions 0.2×
- Social Sciences 0.2×
- Environmental Science 0.1×
Which keywords describe research at Vifor Pharma (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chronic Kidney Disease, Inflammation, Heart Failure, Cancer Therapy, Immunotherapy, Oxidative Stress, Cardiovascular Disease and Anemia.
- Gene Therapy
- Filaggrin
- Vaccine
- Health Utility Measures
- Drug Development Costs
- Cancer Treatment
- Tumor Regression
- Iron Regulation
- Nutrition
- Drug Delivery
- Rituximab
- Prognostic Factors
- Renin-Angiotensin-Aldosterone System Inhibitors
- Hyperkalemia
- Nanoparticles
- Anemia
- Immunotherapy
- Cancer Therapy
- Oxidative Stress
- Epidemiology
- Inflammation
- Chronic Kidney Disease
- Heart Failure
- Cardiovascular Disease
- Quality of Life
- Iron Deficiency
- Clinical Trials
- Neuroprotection
- Neurological Disorders
- Immune Response
- Tumor Targeting
- Lymphoma
- Hepcidin
- Toxicity
- Cancer Immunotherapy
- Cost-effectiveness Analysis
- Generic Drugs
- Immune Dysregulation
- Cell Death
- Skin Microbiome
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Inflammation5▲ 3.8×18 topics
- Epidemiology4▲ 1.53×18 topics
- Chronic Kidney Disease3▲ 23×5 topics
- Oxidative Stress3▲ 3.5×11 topics
- Heart Failure3▲ 13×4 topics
- Cancer Therapy3▲ 8.7×14 topics
- Cardiovascular Disease3▲ 4.4×9 topics
- Immunotherapy3▲ 6.5×10 topics
- Quality of Life2▲ 2.6×6 topics
- Anemia2▲ 38×2 topics
- Iron Deficiency2▲ 70×2 topics
- Nanoparticles2▲ 2.6×6 topics
- Clinical Trials2▲ 4.6×8 topics
- Hyperkalemia2▲ 211×1 topic
- Neuroprotection2▲ 8.8×3 topics
- Renin-Angiotensin-Aldosterone System Inhibitors2▲ 211×1 topic
- Neurological Disorders2▲ 5.2×5 topics
- Prognostic Factors2▲ 6.7×7 topics
- Immune Response2▲ 4.9×8 topics
- Rituximab2▲ 18×3 topics
- Tumor Targeting2▲ 16×3 topics
- Drug Delivery2▲ 4.8×3 topics
- Lymphoma1▲ 15×2 topics
- Nutrition1▲ 5.2×4 topics
- Hepcidin1▲ 58×1 topic
- Iron Regulation1▲ 58×1 topic
- Toxicity1▲ 5.1×3 topics
- Tumor Regression1▲ 20×2 topics
- Cancer Immunotherapy1▲ 14×2 topics
- Cancer Treatment1▲ 9.2×4 topics
- Cost-effectiveness Analysis1▲ 25×1 topic
- Drug Development Costs1▲ 79×1 topic
- Generic Drugs1▲ 79×1 topic
- Health Utility Measures1▲ 25×1 topic
- Immune Dysregulation1▲ 26×2 topics
- Vaccine1▲ 5.3×4 topics
- Cell Death1▲ 8.4×5 topics
- Filaggrin1▲ 40×1 topic
- Skin Microbiome1▲ 40×1 topic
- Gene Therapy1▲ 9.4×4 topics
Which research topics does Vifor Pharma (United States) publish most on?
By volume in 2022–2025: Potassium and Related Disorders, Iron Metabolism and Disorders, Pharmaceutical Economics and Policy and Health Systems, Economic Evaluations, Quality of Life.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Potassium and Related Disorders Pulmonary and Respiratory Medicine 2 works
- 2 Iron Metabolism and Disorders Hematology 1 works
- 3 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
- 4 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
- 5 Dermatology and Skin Diseases Dermatology 1 works
- 6 CAR-T cell therapy research Oncology 1 works
- 7 COVID-19 diagnosis using AI Radiology, Nuclear Medicine and Imaging 1 works
- 8 Innovation and Socioeconomic Development Business and International Management 1 works
- 9 Hemoglobinopathies and Related Disorders Genetics 1 works
- 10 Erythropoietin and Anemia Treatment Hematology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Vifor Pharma (United States)'s research output changed?
Output in 2018–2022 was 49% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Somerset
- ProCure (United States)
- Montgomery High School
- University Orthopaedic Associates
- Catalent (United States)
- Terumo (United States)
- Orthopaedic Center of New Jersey
- NEI Corporation (United States)
- Light Age (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.